Current status of cancer immunotherapy
To prove clinical benefits of cancer vaccine is currently difficult, except for one phase III trial has documented improved overall survival with the vaccine, Sipuleucel‑T, although induction of anti-tumor immune responses through cancer vaccine is theoretically promising and would be straightforwar...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
GN Corporation Limited
2014-04-01
|
| Col·lecció: | Journal of Stem Cells and Regenerative Medicine |
| Matèries: | |
| Accés en línia: | http://www.pubstemcell.com/monthly/010010200003.htm |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|